LoxiGen, Inc. is a drug development company bringing breakthrough targeted therapies for the treatment of aggressive cancers (e.g., triple-negative breast cancer or kidney cancer) and fibrosis-driven diseases.
Our next generation LOX inhibitors break down the rigid tissue surrounding the tumor and help drugs better penetrate cancer tissues in addition to blocking key intracellular processes.
Our LOX inhibitors are the best-in-class with excellent drug-like properties and they effectively target drug-resistant solid tumors.
Developing Innovative Cancer Therapies
LoxiGen develops innovative cancer therapies targeting lysyl oxidase (LOX) family proteins in hard-to-treat cancers.
Validated Mechanisms of Action for New Cancer Treatment Modalities
LoxiGen has developed a series of drug candidates that exhibit a unique and validated mechanism of action towards LOX function in a wide range of cancers and fibrosis-driven diseases.
Targeted Precision Treatment Approach
LoxiGen is dedicated to developing inhibitors of lysyl oxidases utilizing our unique expertise in the fields of extracellular matrix (ECM) remodeling and the biology of lysyl oxidase-driven processes.